Pilot Decentralized Clinical Trial in Men and Pre and Post-menopausal Women With Breast Cancer and a Specific Mutation (PIK3CA) Treated With Alpelisib in Combination With Fulvestrant
Status: TERMINATED
Study type: INTERVENTIONAL
Conditions: Advanced Breast Cancer
Interventions: DRUG: Alpelisib|DRUG: fulvestrant
Sponsor: Novartis Pharmaceuticals